NewsPronto

 
The Times


.

ACN Newswire

Read more press releases from ACN Newswire here

Nanobiotix plans to conduct its first clinical trial with NBTXR3 in combination with immune checkpoint inhibitors in the U.S.

  • Written by ACN Newswire

image

- Multi-arm trial targets sub-population of advanced lung, and head and neck cancer patients- Medium term objective is to transform non-responders into checkpoint inhibitor responders while improving patient benefits- Trial aims to evaluate the ability of NBTXR3 to generate an abscopal effect- Expands the potential for NBTXR3, including recurrent...

Read more: Nanobiotix plans to conduct its first clinical trial with NBTXR3 in combination with immune...